Document is current
Any future updates will be listed below
-
Authors
Hua, Xinwei
McGoldrick, Jessica
Nakrour, Nour
Staller, Kyle
Chung, Daniel Chulyong
Xavier, Ramnik Joseph
Khalili, Hamed http://orcid.org/0000-0002-7956-6941
-
Funding
Funding for this research was provided by:
National Institute of Health (R01 AG068390)
Center for the study of inflammatory bowel disease (DK043351)
Karolinska Institute
- License Information
-
More Information
Article History
Received: 3 August 2023
Accepted: 7 August 2024
First Online: 23 August 2024
Declarations
:
: This study was approved by Partners Human Research Committee, the Institutional Review Board of Mass General Brigham and was conducted in compliance to the principles of the Helsinki Declaration. All participants provided written informed consent before enrollment.
: Not applicable.
: HK has received grant funding from Pfizer and Takeda Pharmaceuticals and consulting fees from Abbvie, Takeda, and Aditium Bio. HK also serves on the clinical advisory board of CylindarHealth. KS has received research funding from Ironwood and Urovant and has served as a consultant to Anji, Ardelyx, Arena, Gelesis, Restalsis, Sanofi, and Takeda. RJX is a cofounder of Jnana Therapeutics, Celsius Therapeutics, director of Moonlake Immuno Therapeutics, SAB member at Nestle. None of the industry funding is related to the current study. The remaining authors declare that they do not have any competing interests.
